SBRT for early-stage glottic larynx cancer—Initial clinical outcomes from a phase I clinical trial

PURPOSE: To confirm safety and feasibility of hypofractionated SBRT for early-stage glottic laryngeal cancer. METHODS: Twenty consecutive patients with cTis-T2N0M0 carcinoma of glottic larynx were enrolled. Patients entered dose-fractionation cohorts of incrementally shorter bio-equivalent schedules...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartz, David L., Sosa, Alan, Chun, Stephen G., Ding, Chiuxiong, Xie, Xian-Jin, Nedzi, Lucien A., Timmerman, Robert D., Sumer, Baran D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333979/
https://www.ncbi.nlm.nih.gov/pubmed/28253270
http://dx.doi.org/10.1371/journal.pone.0172055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5333979/
https://www.ncbi.nlm.nih.gov/pubmed/28253270
http://dx.doi.org/10.1371/journal.pone.0172055

Ejemplares similares